Change in Eosinophil Count in Patients with Heart Failure Treated with Anakinra.
cardiorespiratory fitness
eosinophils
exercise test
heart failure
injection site reaction
interleukin-1
interleukin-1 receptor antagonist protein
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
11 04 2023
11 04 2023
Historique:
received:
24
03
2023
revised:
07
04
2023
accepted:
10
04
2023
medline:
17
5
2023
pubmed:
16
5
2023
entrez:
16
5
2023
Statut:
epublish
Résumé
Interleukin-1 blockade with anakinra leads to a transient increase in eosinophil blood count (eosinophils) in patients with acute myocardial infarction. We aimed to investigate the effect of anakinra on changes in eosinophils in patients with heart failure (HF) and their correlation with cardiorespiratory fitness (CRF). We measured eosinophils in 64 patients with HF (50% females), 55 (51-63) years of age, before and after treatment, and, in a subset of 41 patients, also after treatment cessation. We also evaluated CRF, measuring peak oxygen consumption (VO Treatment with anakinra significantly and transiently increased eosinophils, from 0.2 [0.1-0.3] to 0.3 [0.1-0.4] × 10 Patients with HF treated with anakinra experience a transient increase in eosinophils, which is associated with ISR and a greater improvement in peak VO
Sections du résumé
BACKGROUND
Interleukin-1 blockade with anakinra leads to a transient increase in eosinophil blood count (eosinophils) in patients with acute myocardial infarction. We aimed to investigate the effect of anakinra on changes in eosinophils in patients with heart failure (HF) and their correlation with cardiorespiratory fitness (CRF).
METHODS
We measured eosinophils in 64 patients with HF (50% females), 55 (51-63) years of age, before and after treatment, and, in a subset of 41 patients, also after treatment cessation. We also evaluated CRF, measuring peak oxygen consumption (VO
RESULTS
Treatment with anakinra significantly and transiently increased eosinophils, from 0.2 [0.1-0.3] to 0.3 [0.1-0.4] × 10
CONCLUSION
Patients with HF treated with anakinra experience a transient increase in eosinophils, which is associated with ISR and a greater improvement in peak VO
Identifiants
pubmed: 37190038
pii: cells12081129
doi: 10.3390/cells12081129
pmc: PMC10137267
pii:
doi:
Substances chimiques
Interleukin 1 Receptor Antagonist Protein
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCRR NIH HHS
ID : KL2RR031989
Pays : United States
Organisme : NHLBI NIH HHS
ID : 1R34HL118348
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1TR000058
Pays : United States
Organisme : NHLBI NIH HHS
ID : 1R34HL117026
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR031990
Pays : United States
Références
Am J Cardiol. 1989 Sep 15;64(10):651-4
pubmed: 2782256
Clin Exp Allergy. 2008 Aug;38(8):1254-63
pubmed: 18727793
Am J Cardiol. 1993 May 1;71(12):1106-7
pubmed: 8475878
Circ Heart Fail. 2017 Nov;10(11):
pubmed: 29141858
J Cardiovasc Pharmacol. 2022 Jun 01;79(6):774-780
pubmed: 35170493
PLoS One. 2012;7(3):e33438
pubmed: 22438931
Am J Cardiol. 2014 Jan 15;113(2):321-327
pubmed: 24262762
J Allergy Clin Immunol Glob. 2022 Nov;1(4):233-240
pubmed: 36466741
Nat Commun. 2020 Dec 16;11(1):6396
pubmed: 33328477
Br J Dermatol. 2005 Aug;153(2):417-23
pubmed: 16086759
Open Heart. 2016 Sep 05;3(2):e000477
pubmed: 27621833
J Am Heart Assoc. 2020 Mar 3;9(5):e014941
pubmed: 32122219
Am J Hematol. 2019 Oct;94(10):1149-1167
pubmed: 31423623
Sci Rep. 2022 Jan 24;12(1):1254
pubmed: 35075216
Circ Heart Fail. 2018 Aug;11(8):e005036
pubmed: 30354558
Rheumatol Int. 2012 Feb;32(2):295-9
pubmed: 21881988
Am J Med. 2019 Dec;132(12):e827-e834
pubmed: 31152721
Eur Heart J Cardiovasc Pharmacother. 2022 Aug 11;8(5):503-510
pubmed: 34617567
Annu Rev Pathol. 2020 Jan 24;15:179-209
pubmed: 31977298
Am J Cardiol. 2013 May 15;111(10):1394-400
pubmed: 23453459
Medicina (Kaunas). 2022 Oct 15;58(10):
pubmed: 36295615